Pharmacokinetics of Zolpidem Orodispersible Tablet

Inclusion Criteria: * Male or female study participants, aged above 18 years-old; women cannot be pregnant or breastfeeding * Body mass index (BMI) greater than or equal to 19 and less than or equal to 28.75 Kg/m2 * Good health conditions or without significant diseases, according to best medical judgement, according to protocol requirements and study evaluations: medical history, blood pressure and heart rate measurements, physical examination, electrocardiogram (ECG) and complementary laboratory tests * Ability to understand the nature and objectives of the trial, including risks and adverse events; willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by Informed Consent Form signature. Exclusion Criteria: * Known hypersensitivity to the investigational product (Zolpidem) or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug * History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism * Chronic therapy with any drugs, except oral contraceptives * History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic or psychiatric disease; hypotension or hypertension, of any etiology, that requires pharmacological treatment; history of myocardial infarction, angina and/or heart failure * Electrocardiographic findings that, at investigator criteria, are not recommended for study participation * Deviations on screening laboratory results that are considered as clinically relevant by the researcher * Smoking * Intake of more that 5 cups of coffee or tea per day * Unusual food habits, e.g., vegetarians * History of drugs and alcohol addiction or excessive alcohol consumption (\> 35 g/day) * Use of regular medications within 2 weeks prior study enrollment or use of any medications within one week prior to study enrollment, except oral contraceptives or cases which, based on drug's or metabolite's half-life, complete elimination can be assumed * Hospitalization for any reasons up to 8 weeks before trial * Treatment, within 6 months before the trial, with any drugs with known and well-established toxic potential to major organs * Participation in any other experimental research or administration of any experimental drug within 6 months before this trial * Donation or loss of 450 mL or more of blood within 3 months before this trial or 3 donations (women)/4 donations (men) of blood within 12 months before this trial * Any condition, according to investigator's best judgement, that prevents the subject to participate in the trial * Pregnancy, labor or miscarriage with 12 weeks before admission predicted date.